文献速递免疫规划妇幼与学校卫生

MenACWY-TT四价脑膜炎球菌结合疫苗与常规儿童疫苗联合接种在健康婴儿中的免疫原性和安全性:一项III期随机研究

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
PubMed 文献 · Vaccine · 2018-05-18

在黎巴嫩和墨西哥2个中心开展的III期b随机研究纳入750名健康婴儿,按2:1:1随机接受MenACWY-TT的3+1、1+1或15-18月龄单剂次接种程序,同时接种PHiD-CV和DTPa-IPV/Hib。结果显示基础免疫后1个月ACWY3+1组各血清群rSBA滴度≥8的婴儿百分比95%CI下限>80%,15-18月龄接种后所有组≥96.3%的参与者rSBA滴度≥8,联合接种未影响常规疫苗免疫应答,不良反应发生率组间相似,未报告疫苗相关严重不良事件。

要点

  • ACWY3+1组基础免疫后1个月各血清群rSBA滴度≥8的婴儿百分比95%CI下限>80%。
  • 15-18月龄接种MenACWY-TT后所有组≥96.3%的参与者rSBA滴度≥8,与既往剂次无关。
  • 所有组严重不良事件报告63/750例,研究者认为均与疫苗无关。

核心结论

  • 婴儿期接种3剂或1剂MenACWY-TT并与常规儿童疫苗联合接种具有免疫原性且耐受性良好。

研究设计与样本

  • III期b随机研究(NCT01340898),在黎巴嫩和墨西哥2个中心开展,750名健康婴儿按2:1:1随机分配接受MenACWY-TT的3+1、1+1或15-18月龄单剂次接种程序。
  • 所有婴儿在2、4、6、15-18月龄接种PHiD-CV和DTPa-IPV/Hib。

主要发现

  • 基础免疫后1个月,ACWY3+1组各血清群rSBA滴度≥8的婴儿百分比95%CI下限>80%。
  • 7月龄时,≥93.9%的MenACWY-TT基础免疫婴儿rSBA滴度≥8。
  • 15-18月龄接种MenACWY-TT后,所有组≥96.3%的参与者rSBA滴度≥8,与既往接种剂次无关。
  • 基础免疫后和加强/单剂接种后hSBA滴度≥4的婴儿百分比分别≥87.2%和≥89.7%。
  • 联合接种MenACWY-TT似乎未影响婴儿对PHiD-CV和DTPa-IPV/Hib的免疫应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive meningococcal disease has a high burden in young children, particularly during infancy. We investigated the immunogenicity and safety of a quadrivalent meningococcal conjugated vaccine (MenACWY-TT) co-administered with routine vaccines in healthy infants. METHODS: In this phase IIIb study (NCT01340898) conducted in 2 centers in Lebanon and Mexico, 750 infants were randomized (2:1:1) to receive MenACWY-TT according to 3 schedules: 3+1 (at ages 2, 4, 6 and 15-18 months; group ACWY3+1); 1+1 (at 6 and 15-18 months; group ACWY1+1) or single-dose at 15-18 months (group ACWY1). All infants received PHiD-CV and DTPa-IPV/Hib at ages 2, 4, 6, 15-18 months. Immune responses to MenACWY-TT were assessed by rSBA and hSBA at 7 months (groups ACWY3+1, ACWY1+1) and pre- and post-vaccination at 15-18 months of age (all groups). Immune responses to co-administered vaccines, reactogenicity and safety were also evaluated. RESULTS: Immunogenicity of MenACWY-TT at 1 month post-primary vaccination was demonstrated in group ACWY3+1: the lower limit of the 95% confidence interval for the percentage of infants with rSBA titers ≥8 was >80% for each serogroup. At 7 months of age, ≥93.9% of MenACWY-TT-primed infants had rSBA titers ≥8. Post-MenACWY-TT vaccination at age 15-18 months, ≥96.3% of participants in all groups had rSBA titers ≥8, regardless of the number of doses received previously. The percentage of infants with hSBA titers ≥4 were ≥87.2% and ≥89.7% at post-primary and booster/single-dose vaccination, respectively. Immune responses to PHiD-CV and DTPa-IPV/Hib did not seem impacted by co-administration with MenACWY-TT in infancy. The incidence of all adverse events was similar among groups. Serious adverse events were reported for 63/750 children in all groups; none were considered vaccine-related by investigators. CONCLUSION: Primary vaccination with 3 or 1 dose(s) of MenACWY-TT when co-administered with routine pediatric vaccines in infants is immunogenic and well-tolerated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dbaibo G, Tinoco Favila JC, Traskine M, et al. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study. Vaccine. 2018. PMID: 29784470. doi:10.1016/j.vaccine.2018.05.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。